Destiny Pharma appoints three Non-Executive Directors

Brighton, United Kingdom – 26 May 2022  Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointments of James Stearns, Aled Williams and Nigel Brooksby as Non-Executive Directors with effect from 1 June 2022. James Stearns is replacing Dr Huaizheng Peng. The Company has been looking to add Non-Executive Directors following the retirement of Peter Morgan in March this year and has decided to add Aled and Nigel as two new appointments. The Board has expanded its skills and experience base through these additions and is well positioned to continue to deliver its strategy.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH